Veregen granted MA in the Czech Republic

Medigene's Veregen (sinecatechins), an ointment used in the topical treatment of external genital warts, has obtained market approval (MA) in the Czech Republic. Medigene's marketing partner, Nordic Pharma, is planning to launch Veregen in the Czech Republic, Poland, Hungary and Slovakia during 2013, upon conclusion of the reimbursable price-fixing procedure by the responsible authority.

Veregen is already being marketed in the US, Germany, Switzerland, Austria and Spain by the sales partners, Fougera, Abbott and Bial-Portela. Market approvals and the launch in additional countries are pending in 2013. Medigene has entered into several marketing partnerships for Veregen across Europe, Asia, and America, and is planning to continue this global licensing strategy to further exploit the product's market potential.


Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.